RheOx Registry Study in Europe

Launched by GALA THERAPEUTICS, INC. · Nov 27, 2019

Keywords

ClinConnect Summary

The RheOx Registry Study is a research project happening in Europe that aims to gather information about the safety and effectiveness of a treatment called RheOx for patients with chronic bronchitis and chronic obstructive pulmonary disease (COPD). This study is currently looking for participants who are experiencing moderate to severe chronic bronchitis. If you or a family member have this condition and are interested in helping researchers learn more about RheOx, you might be eligible to join the study.

To participate, it’s important that you do not have certain heart devices like pacemakers or any serious heart rhythm issues. Participants will be monitored to see how well the treatment works and to ensure it is safe for them. This study is a great opportunity for individuals with chronic bronchitis to contribute to medical research while potentially receiving valuable care. If you have any questions or want to know more about participating, please reach out to the study team.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient has moderate to severe Chronic Bronchitis
• Exclusion Criteria:
• • Patient has an implantable cardioverter defibrillator, pacemaker, or any other implantable electronic device.
• • Patient has history of ventricular tachyarrhythmia or any clinically significant atrial tachyarrhythmia (i.e., abnormality with vital signs) and/or history of type II second or third degree AV block.
• • Patient has airway stent(s), valves, coils, or other lung implant/prosthesis.